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Emory University School of Medicine, Atlanta, Georgia, USAIntroduction: After renal transplantation, decreased renal function is associated with increased risk of
cardiovascular disease, graft loss, and mortality. We investigated whether declining renal function was
associated with hospitalization after transplantation.
Methods: Adult, ﬁrst-time, kidney transplant recipients between 2004 and 2006 from the United Network
for Organ Sharing database and hospitalizations 1 year after the 6-month posttransplant follow-up visit
were examined. Generalized linear models explored the relationship between estimated glomerular
ﬁltration rate (eGFR) measured at 6 months and the number of hospitalizations in the following year.
Results: Of 15,778 kidney transplant recipients, 19.1% were admitted in the year after the 6-month
follow-up visit. Among those hospitalized, the mean number of hospitalizations was 1.71, which
increased with decreasing eGFR. In multivariable models, a decrease in eGFR was signiﬁcantly associated
with increased hospitalizations: for every 10 ml/min per 1.73 m2 decrease in eGFR, there was an 11%
increase in hospitalization rate (P < 0.001). Lower eGFR after the ﬁrst 6 months after transplantation was
associated with an increase in late hospitalizations among adult kidney transplant recipients.
Discussion: Identifying patients with declining eGFR and other risk factors may help prevent morbidity and
mortality associated with hospitalization after transplantation.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).T he treatment of end-stage renal disease requiresrenal replacement therapy in the form of dialysis
or renal transplantation; transplantation is the
preferred treatment, and is associated with lower mor-
tality and improved quality of life.1 Prior studies have
shown that estimated glomerular ﬁltration rate (eGFR)
is the best predictor of long-term graft function among
transplant recipients2,3 and that declining eGFR after
kidney transplantation is associated with higher health
care costs;4,5 however, the association between
declining eGFR and posttransplantation hospitalization
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International Reports (2016) 1, 269–278used as a proxy of poor health outcomes after renal
transplantation. According to an analysis of Medicare
claims data from 2003 to 2004, 1 of 5 Medicare beneﬁ-
ciaries were rehospitalized within 30 days of discharge
at a cost of $17.4 billion.6
Prior studies have found that 30-day readmission or
“early readmission” after kidney transplantation is
associated with increased morbidity, costs, and
transition-of-care errors7 in addition to increased graft
loss and mortality among patients with Medicare pri-
mary insurance.8,9 Despite a sizeable amount of
research on early hospital readmission among kidney
transplant recipients, to our knowledge, no study has
examined eGFR as a predictor of hospital readmission
beyond 6 months after transplantation. The purpose of
this study was to determine whether the eGFR 6
months after renal transplantation was associated with
“late” all-cause hospitalization approximately 1 year269
Potential participants assessed for eligibility  
(n = 30,614)
*Patients with transplant between 6/30/2004 and 
1/1/2006
Number meeting eligibility criteria 
(n= 20,135)
*Adult, first-time, kidney-only, single-organ 
transplant recipients with 1 year of follow-up 
Number with valid baseline visit  
(6-month) information 
(n = 16,481) 
Number analyzed
(n = 15,778)
Missing exposure or outcome   (n = 703)
Missing or invlaid eGFR n = 385
Missing or invalid hospitalizations n = 318
Losses to follow-up (n = 3654)
Died during follow-up n = 369
No follow-up visits n = 82 
No 6-month visit n= 3,203
Excluded (n = 10,479)
Previous transplant recipient n = 4444
Under 18 years old n = 2256
Nonkidney transplant n = 2865
Multiple organ transplantarion n = 914
Figure 1. Flow chart of exclusion criteria for study population. eGFR,
estimated glomerular ﬁltration rate.
CLINICAL RESEARCH FM Keong et al.: eGFR and Hospitalizationafter the 6-month posttransplant data collection point.
In addition, because prior studies of hospitalization
among kidney transplant recipients have been con-
ducted among patients receiving Medicare as primary
insurance only, we sought to characterize the key risk
factors for late hospital readmission among a popula-
tion that is more generalizable to the entire US kidney
transplant recipient population.
METHODS
Study Population and Data Sources
The United Network for Organ Sharing (UNOS) is a
nonproﬁt organization that maintains the Organ Procure-
ment and Transplantation Network database. Organ
Procurement and Transplantation Network contains in-
formation regarding every organ donation and transplant
event in the United States since 1 October 1987. For this
study, we used the Standard Transplant Analysis and
Research ﬁles based on Organ Procurement and Trans-
plantation Network data for kidney, pancreas, and
kidney-pancreaswaiting list and transplant and/or follow-
up patients between 1 October 1987 and 31 October 2011.
We restricted our analyses to data from 30 June 2004
to 1 January 2007 for adult (18 years or older), ﬁrst-
time, kidney-only transplant recipients where the
transplant was received before 1 January 2006, based
on the availability of data regarding hospitalizations
during the follow-up period, which was a required ﬁeld
on UNOS transplant follow-up forms until 1 January
2007. Our follow-up time of 2 years after trans-
plantation (18 months after the 6-month “baseline” for
this study) was also chosen based on the availability of
hospitalization data. Whereas 95% of patients had
hospitalization follow-up data at 2 years after trans-
plantation, fewer than half of participants had hospi-
talization data after this time point. Figure 1 shows
exclusion and selection criteria. Analyses were further
restricted by excluding patients with missing infor-
mation on both the exposure—eGFR (n ¼ 302)—and
outcome—number of hospitalizations during the year
after the 6-month post-renal-transplantation follow-up
(n ¼ 318). Next, patients who died (n ¼ 369) or were
lost to follow-up (n ¼ 82) during the study period were
similarly excluded. Unlikely, values for eGFR (>125
ml/min per 1.73 m2) were set to missing (n ¼ 83). The
patients who were excluded for missing data on
exposure or outcome were compared with those who
were included in this analysis and found to be similar.
Primary Exposure
The primary exposure was eGFR collected on the UNOS
transplant recipient follow-up forms at 6 months, and
calculated using the 4-variable Modiﬁcation of Diet in
Renal Disease equation.10 The eGFR was calculated270from serum creatinine measured and reported by
transplant centers to UNOS at regularly scheduled data
collection time points. The 6-month posttransplant
follow-up creatinine value served as the baseline time
point for calculation of eGFR. Laboratory values re-
ported between 135 and 225 days (6 months  45 days)
after transplantation were considered to be the 6-
month follow-up value. If a patient had multiple
follow-up labs reported during this time period, the
ﬁrst value was used as the baseline.
Primary Outcome
The primary outcome for this study was the number
of hospitalizations that occurred in the year after the
6-month time point after renal transplantation, that is,
hospitalizations that occurred up to 18 months after
transplantation. Rehospitalization after 6 months, as
opposed to 30 days, is less likely to be the result of
surgical complications from the transplant procedure,
as patients stabilize over time. Only hospitalizations
after this baseline time point were considered for these
analyses to ensure that eGFR was measured before
rehospitalization.Kidney International Reports (2016) 1, 269–278
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Figure 2. Distribution of study participants by estimated glomerular
ﬁltration rate (eGFR) cut point at 6 months after transplantation.
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We performed descriptive analyses of the relationship
between the 6-month eGFR and the number of late
hospitalizations, controlling for several potential
confounders including recipient characteristics
(demographics, clinical characteristics, comorbidities),
donor characteristics, transplant characteristics, and
complications. Bivariate analyses by standard eGFR cut
points and by the number of hospitalizations were
conducted using t-tests to compare continuous vari-
ables and c2 tests for categorical variables. Covariates
considered as potential confounders included recipient
characteristics: age, race (white, black, Asian, Hispanic,
other), sex, body mass index (continuous),11 education
level (high school or less, attended college, associate
and/or bachelor degree, post-college graduate degree,
missing), primary form of payment (private insurance,
public insurance, missing), primary diagnosis (diabetes
related, hypertension related, glomerular nephritis,
secondary glomerular nephritis, hereditary and/or
congenital disease, other), previous dialysis (yes, no),
diabetes (yes, no, missing), cancer or malignancy (yes,
no, missing), total serum albumin, serum creatinine;
donor characteristics: donor age, donor height, donor
type (living, deceased, deceased expanded criteria),
donor diabetes (yes, no, missing), and donor hyper-
tension (yes, no, missing); transplant characteristics:
length of stay (at time of transplant in days), human
leukocyte antigen (HLA) match level (zero to six,
missing), cold ischemia time (0–10, 11–20, 21–30,
>30 hours, missing), panel-reactive antibody (0, 1–20,
21–80, 80þ); and complications: previous hospitaliza-
tion (hospitalization during the ﬁrst 6 months after
transplantation) (yes, no) acute rejection (yes, no),
delayed graft function (yes, no). “Missing” was
considered as a separate response category for cova-
riates as noted. No patients in our sample had experi-
enced an allograft loss; therefore, loss of allograft was
not included in these analyses.
The number of late hospitalizations was modeled
using a zero-inﬂated Poisson regression (generalized
linear model using SAS Proc Genmod [SAS Version 9.3,
Cary, NC]). For the ﬁnal multivariable model, we
included variables that were signiﬁcantly associated
with both exposure and outcome during descriptive
analyses and known potential confounders from a re-
view of the literature.12 The full model included the
main exposure variable—eGFR—and the following
variables—race, recipient age, sex, body mass index
category, insurance type, education, HLA match level,
cold ischemia time, length of stay (at the time of
transplant), serum albumin, diabetes status, hyperten-
sion status, primary diagnosis, delayed graft function,
pretransplant dialysis, before hospitalization, donorKidney International Reports (2016) 1, 269–278age, donor type, donor hypertension, and donor dia-
betes. Collinearity for this model was evaluated by
assessing whether condition indices were high (>30)
with variance decomposition proportions for variables
excluding the intercept greater than 0.50. No variables
in the full model violated these assumptions, and thus
the full model included all variables stated above.
Sensitivity Analyses
We conducted several sensitivity analyses to examine
the robustness of ﬁndings. First, we repeated analyses
using the chronic kidney disease-Epi formula to
calculate the eGFR. We also repeated analyses
including patients who (i) died during the study
follow-up period, (ii) had previously received a trans-
plant, and (ii) had received a multi-organ transplant.
Statistical Signiﬁcance
All tests were 2-sided, with an a ¼ 0.05, and analyses
were conducted using SAS version 9.3 (SAS Institute,
Cary, NC). The Emory Institutional Review Board
approved this study.
RESULTS
A total of 15,778 adult, ﬁrst-time, kidney-only trans-
plant recipients met the inclusion criteria for this
analysis. The mean age of the study population was 50
years (13.5), 24.2% (n ¼ 3812) were black, 60.5%
were men (n ¼ 9552), and 57.8% had public insurance
(n ¼ 9113).
Figure 2 shows the distribution of patients by eGFR
category. Patients in the lowest eGFR category were
more likely to be black (40.9% compared with 24.2%
in the study sample as a whole), older, overweight,
expanded criteria donor recipients, and publicly
insured (Table 1). They were also more likely to have
been readmitted to the hospital (52.7% compared with
19.1% in the study sample). On average, those with271
Table 1. Baseline demographic characteristics by eGFR cut points for adult, ﬁrst-time, kidney-only recipients (United Network for Organ Sharing
2004–2007)
Study
population
By eGFR cut points
P value
<15 15--29 30--44 45--59 60--89 90--125
N % N % N % N % N % N % N %
15,778 93 0.59 763 4.84 3308 20.97 5437 34.46 5464 34.63 713 4.52
Recipient characteristics Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Age (yr) 49.6 13.5 50.0 13.5 52.9 12.8 51.9 12.8 49.9 13.2 47.7 13.8 46.6 14.3 <0.001
BMI (kg/m2) 27.4 5.6 27.9 5.6 28.8 6.2 28.2 5.6 27.7 5.7 26.6 5.4 25.6 5.4 <0.001
Total serum albumin (g/dl) 3.9 0.6 3.9 0.5 3.9 0.6 3.9 0.6 3.9 0.6 3.9 0.6 3.9 0.7 <0.001
Serum creatinine (mg/dl) 1.5 0.7 6.3 2.4 2.8 0.7 1.9 0.3 1.4 0.2 1.1 0.2 0.8 0.1 <0.001
N % N % N % N % N % N % N %
Race/ethnicity <0.001
White 8726 55.3 38 40.9 438 57.4 2042 61.7 3192 58.7 2752 50.4 264 37.0
Black 3812 24.2 38 40.9 186 24.4 688 20.8 1189 21.9 1458 26.7 253 35.5
Hispanic 2119 13.4 12 12.9 84 11.0 349 10.6 684 12.6 857 15.7 133 18.7
Asian 796 5.0 3 3.2 41 5.4 157 4.8 258 4.8 285 5.2 52 7.3
Other 325 2.1 2 2.2 14 1.8 72 2.2 114 2.1 112 2.1 11 1.5
Sex <0.001
Male 9552 60.5 52 55.9 403 52.8 1996 60.3 3422 62.9 3276 60.0 403 56.5
Educationa 2578a <0.001
High school (9–12) or less 7057 53.5 42 55.3 351 55.1 1430 51.8 2361 51.9 2512 55.0 361 59.4
Attended college/technical school 3169 24.0 19 25.0 148 23.2 650 23.5 1095 24.1 1118 24.5 139 22.9
Associate/bachelor degree 2089 15.8 8 10.5 89 14.0 467 16.9 785 17.3 662 14.5 78 12.8
Post-college graduate degree 885 6.7 7 9.2 49 7.7 215 7.8 307 6.8 277 6.1 30 4.9
Insurance <0.001
Private insurance 6,629 42.0 26 28.0 271 35.5 1446 43.7 2383 43.8 2276 41.7 227 31.8
Public insurance 9113 57.8 67 72.0 492 64.5 1859 56.2 3045 56.0 3169 58.0 481 67.5
Other 36 0.2 – – – – 3 0.1 9 0.2 19 0.4 5 0.7
Primary diagnosis 1719a <0.001
Diabetes related 3825 24.3 23 21.5 209 26.9 683 24.5 1102 24.3 1100 23.6 168 25.8
Hypertension related 3052 22.6 31 29.0 167 21.5 609 21.8 998 22.0 1080 23.2 167 25.6
Glomerular nephritis 2521 18.7 15 14.0 128 16.5 509 18.2 903 19.9 855 18.4 111 17.0
Secondary glomerular nephritis 596 4.4 2 1.9 38 4.9 106 3.8 179 4.0 234 5.0 37 5.7
Hereditary and/or congenital
diseases
1863 13.8 12 11.2 93 12.0 441 15.8 654 14.4 598 12.9 65 10.0
Other 2202 16.3 24 22.4 141 18.2 445 15.9 701 15.5 787 16.9 104 16.0
Previous dialysisa 349a <0.001
Yes 12,118 79.1 92 79.3 702 85.4 2512 78.9 4025 77.1 4174 79.4 613 85.5
Previous malignancy 0.29
Yes 562 3.8 2 2.5 32 4.8 139 4.8 206 4.4 183 3.8 24 3.8
Diabetesa 303a 0.31
Yes 4828 31.2 25 27.5 258 34.7 1014 31.5 1644 30.8 1660 30.9 227 32.2
Cerebrovascular diseasea 878a 0.27
Yes 392 2.6 5 6.2 17 2.4 74 2.4 129 2.5 147 2.8 20 3.0
Donor characteristics Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Donor age (yr) 39.2 14.55 43.6 15.7 48.4 14.2 45.5 14.0 40.3 13.7 34.3 13.4 29.9 12.9 0.50
Donor height (cm) 169.4 14.4 166.1 16.7 168.1 13.1 168.2 13.4 169.4 13.1 170.3 15.6 170.8 18.2 <0.001
N % N % N % N % N % N % N %
Donor type <0.001
Living 6839 43.4 24 25.8 187 24.5 1348 40.8 2595 47.7 2424 44.4 261 36.6
Deceased standard criteria 7374 46.7 46 49.5 351 46.0 1369 41.4 2354 43.3 2817 51.6 437 61.3
Deceased expanded criteria 1565 9.9 23 24.7 225 29.5 591 17.9 488 9.0 223 4.1 15 2.1
Donor diabetesa 310a <0.001
Yes 452 2.88 7 5.9 64 7.6 154 4.7 125 2.3 88 1.6 14 1.9
Donor hypertensiona 355a <0.001
Yes 2274 14.51 32 27.1 298 35.5 733 22.5 693 13.0 465 8.7 53 7.3
Transplant characteristics Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Cold ischemic time (h) 12.9 10.76 15.5 9.0 16.8 11.0 13.8 11.3 12.2 10.5 12.3 10.6 13.2 9.9 <0.001
Length of stay at transplant (d) 7.1 11.89 10.2 9.9 9.0 7.6 7.7 18.1 6.8 7.0 6.6 8.5 7.7 24.3 <0.001
(Continued on next page)
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Table 1. Baseline demographic characteristics by eGFR cut points for adult, first-time, kidney-only recipients (United Network for Organ Sharing
2004–2007) (Continued)
Transplant characteristics Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Peak PRA 8.9 22.0 15.6 29.6 10.5 24.0 9.2 22.4 7.9 20.4 9.1 22.6 10.1 23.2 <0.001
N % N % N % N % N % N % N %
PRA <0.001
0 10,712 68.36 73 61.9 538 64.1 2186 67.1 3725 69.6 3714 69.1 476 65.1
1–20 3081 19.66 19 16.1 183 21.8 670 20.6 1048 19.6 1009 18.8 152 20.8
21–80 1235 7.88 15 12.7 75 8.9 265 8.1 391 7.3 422 7.9 67 9.2
80þ 643 4.1 11 9.3 43 5.1 138 4.2 185 3.5 230 4.3 36 4.9
HLA match levela 53a <0.001
Zero 2759 17.6 21 22.8 176 23.1 589 17.9 947 17.5 906 16.7 120 16.9
One 4267 27.1 28 30.4 233 30.5 985 29.9 1457 26.9 1368 25.1 196 27.5
Two 2737 17.4 14 15.2 136 17.8 566 17.2 943 17.4 946 17.4 132 18.5
Three 3211 20.4 15 16.3 117 15.3 628 19.1 1163 21.5 1153 21.2 135 19.0
Four 1150 7.3 5 5.4 31 4.1 227 6.9 378 7.0 454 8.3 55 7.7
Five 844 5.4 4 4.4 44 5.8 167 5.1 276 5.1 314 5.8 39 5.5
Six 757 4.8 5 5.4 26 3.4 134 4.1 257 4.7 300 5.5 35 4.9
Complications Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Posttransplant hospital readmissions
(number)
0.3 0.9 1.2 1.7 0.7 1.3 0.4 1.0 0.3 0.8 0.3 0.7 0.3 0.8 <0.001
N % N % N % N % N % N % N % <0.001
Previous hospitalization
Yes 3815 24.3 75 63.6 379 45.1 992 30.4 1156 21.6 1055 19.6 158 21.6
Delayed graft function <0.001
Yes 2534 14.3 49 32.2 314 32.0 681 18.7 750 12.6 642 10.6 98 11.3
Acute rejection 370a <0.001
Yes 816 5.3 36 28.6 160 19.2 274 8.6 204 3.9 128 2.4 14 1.9
BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; HLA, human leukocyte antigen; PRA, panel-reactive antibody.
aIncludes missing values.
FM Keong et al.: eGFR and Hospitalization CLINICAL RESEARCHlower eGFR also had a higher total serum albumin, cold
ischemia time, serum creatinine, and length of stay at
the time of transplant compared with the total study
sample. The number of hospital readmissions decreased
among those in higher eGFR categories.
A total of 19.1% of patients were hospitalized at least
once within the year after the 6-month posttransplant
follow-up visit, and 0.7% were hospitalized 5 or more
times in this time period. Black race, Asian race, female
sex, length of stay at the time of transplant, public in-
surance (vs. private insurance), standard and expanded
criteria deceased donor (vs. living donors), diabetic sta-
tus, and increasing donor age were associated with
increased hospitalization (Table 2). Additional covariates
considered are provided in Supplemental Table S1.
Among those hospitalized, the mean number of hospi-
talizations was 1.71 (range, 0–12) and increased mono-
tonically with decreasing eGFR. Patients who were
hospitalized (n¼ 3009) during the year after the 6-month
posttransplant follow-up had a signiﬁcantly lower eGFR
than those whowere not hospitalized (n¼ 12,769) (48.79
vs. 57.45 ml/min per 1.73 m2, respectively) (Figure 3).
In multivariable-adjusted analyses, a 10 ml/min per
1.73 m2 eGFR was signiﬁcantly associated with the total
number of late hospitalizations (Rate Ratio [RR]: 0.89,
95% conﬁdence interval [CI]: 0.89–0.89) within the year
after the 6-month visit; thus, for every 10-unit increaseKidney International Reports (2016) 1, 269–278in eGFR, there was an 11% decrease in the rate of hos-
pitalization (Table 3). After adjusting for other cova-
riates, transplant recipients who were diabetic, who
received dialysis before transplantation, or who expe-
rienced delayed graft function were at increased risk for
hospitalization compared with those who were not.
Patients who had been hospitalized in the ﬁrst months
after transplantation were more than twice as likely to
experience later hospitalization (RR: 2.33, 95% CI: 2.20–
2.48), and those who were on public insurance were
hospitalized 12% more than those on private insurance
(RR: 1.12, 95% CI: 1.09–1.37). Those who had only
attended college and/or technical school or high school
or less were also at increased risk for hospitalization
compared with those with a post-college degree
(RR: 1.16, CI: 1.01–1.33 and RR: 1.13, CI: 0.99–1.29,
respectively) (Table 3). There were no differences by
donor type (living vs. deceased standard vs. deceased
expanded criteria) on the number of hospitalizations.
Sensitivity Analyses
When main multivariable modeling results were
repeated using the chronic kidney disease-Epi equation
instead of Modiﬁcation of Diet in Renal Disease, results
were similar to the main effect estimates (RR: 0.9877,
95% CI: 0.9857–0.9897). Similar results were also
observed when we examined the association between273
Table 2. Basic demographic characteristics by the number of hospitalizations in the year after the 6-month visit for adult, ﬁrst-time, kidney-only
recipients (United Network for Organ Sharing 2004–2007)
Study population
(N [ 15,778)
By number of hospitalizations
P value
Zero
(N [ 12,769)
One
(N [ 1868)
Two
(N [ 623)
Three
(N [ 278)
Four
(N [ 128)
Five or more
(N [ 217)
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Recipient characteristics
eGFR (ml/min per 1.73 m2) 56.6 18.02 57.4 17.62 54.2 18.25 52.1 20.33 49.9 20.73 48.7 18.83 46.8 22.13 <0.001
Mean age (yr) 49.6 13.50 49.5 13.42 49.7 13.48 49.7 14.13 50.3 14.48 49.6 14.86 48.9 15.34 0.90
Mean BMI (kg/m2) 27.4 5.64 27.3 5.60 27.6 5.76 27.7 5.68 27.6 6.06 27.1 5.80 27.7 5.92 0.40
Total serum albumin (g/dl) 3.9 0.60 3.9 0.59 3.9 0.66 3.8 0.59 3.8 0.52 3.9 0.52 3.9 0.50 <0.001
Serum creatinine (mg/dl) 1.5 0.65 1.5 0.57 1.6 0.70 1.7 1.08 1.8 1.20 1.8 0.80 2.0 1.25 <0.001
N % N % N % N % N % N % N %
Ethnicity <0.001
White 8726 55.3 7122 55.8 1008 54.0 338 54.3 143 51.4 66 51.6 49 43.8
Black 3812 24.2 2953 23.1 523 28.0 164 26.3 81 29.1 44 34.4 47 42.0
Hispanic 2119 13.4 1749 13.7 227 12.2 83 13.3 35 12.6 15 11.7 10 8.9
Asian 796 5.0 675 5.3 72 3.9 29 4.7 15 5.4 3 2.3 2 1.8
Other 325 2.1 270 2.1 38 2.0 9 1.4 4 1.4 4 3.6
Sex 0.04
Male 9552 60.5 7796 61.1 1103 59.1 368 59.1 158 56.8 71 55.5 56 50.0
Educationa 2578a 0.69
High school (9–12) or less 7057 53.5 5671 53.1 867 54.9 287 56.4 129 53.3 57 53.8 46 53.5
Attended college/technical school 3169 24.0 2578 24.1 373 23.6 111 21.8 54 22.3 34 32.1 19 22.1
Associate/bachelor degree 2089 15.8 1712 16.0 234 14.8 78 15.3 41 16.9 9 8.5 15 17.4
Post-college graduate degree 885 6.7 717 6.7 105 6.7 33 6.5 18 7.4 6 5.7 6 7.0
Insurance <0.001
Private insurance 6629 42.0 5481 42.9 715 38.3 245 39.3 110 39.6 40 31.3 38 33.9
Public insurance 9113 57.8 7256 56.8 1150 61.6 378 60.7 167 60.1 88 68.8 74 66.1
Other 36 0.2 32 0.3 3 0.2 – – 1 0.4 – – – –
Primary diagnosis 1719a <0.001
Diabetes related 3825 24.3 2337 23.2 530 25.2 223 30.6 106 31.0 53 36.6 36 25.9
Hypertension related 3052 22.6 2284 22.7 482 22.9 162 22.2 77 22.5 18 12.4 29 20.9
Glomerular nephritis 2521 18.7 1952 19.4 363 17.2 107 14.7 58 17.0 21 14.5 20 14.4
Secondary glomerular nephritis 596 4.4 442 4.4 95 4.5 30 4.1 12 3.5 6 4.1 11 7.9
Hereditary/congenital diseases 1863 13.8 1418 14.1 288 13.7 86 11.8 42 12.3 20 13.8 9 6.5
Other 2202 16.3 1624 16.2 348 16.5 122 16.7 47 13.7 27 18.6 34 24.5
Diabetesa 303a <0.0001
Yes 4828 31.2 3782 30.2 608 33.2 230 37.8 110 40.7 50 41.0 48 44.0
Previous malignancy 1984a 0.02
Yes 562 3.8 465 4.2 62 3.7 26 4.7 20 8.1 8 7.1 5 5.2
Previous dialysisa 349 <0.0001
Yes 12,118 79.09 8875 77.99 1951 80.89 695 83.73 319 83.73 143 87.2 135 86.54
Cerebrovascular diseasea 878a 0.15
Yes 392 2.6 301 2.5 52 3.0 24 4.2 7 2.7 5 4.2 3 2.9
Donor characteristics Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Donor age (yr) 39.2 14.55 38.9 14.42 40.0 15.02 41.6 14.90 41.6 15.02 41.5 14.43 44.7 15.16 <0.001
Donor height (cm) 169.4 14.4 169.5 14.5 169.4 14.2 169.4 13.3 169.6 14.9 168.8 13.3 166.8 15.3 0.32
N % N % N % N % N % N % N %
Donor type <0.001
Living 6839 43.4 5674 44.4 733 39.2 243 39.0 97 34.9 50 39.1 42 37.5
Deceased standard criteria 7374 46.7 5915 46.3 924 49.5 289 46.4 142 51.1 59 46.1 45 40.2
Deceased expanded criteria 1565 9.9 1180 9.2 211 11.3 91 14.6 39 14.0 19 14.8 25 22.3
Donor diabetesa 310 <0.001
Yes 452 2.88 298 2.61 80 3.33 37 4.49 20 5.26 4 2.44 13 8.39
Donor hypertensiona 355 <0.001
Yes 2274 14.51 1539 13.51 407 16.94 164 19.88 82 21.75 39 23.78 43 27.56
Transplant characteristics Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Cold ischemic time (h) 12.9 10.76 12.7 10.78 13.3 10.65 13.2 10.40 15.3 11.10 12.2 9.64 15.2 12.23 <0.001
Length of stay at transplant (d) 7.1 11.89 6.9 12.46 7.5 10.07 8.2 7.54 8.2 6.76 8.8 6.24 8.7 6.84 <0.001
(Continued on next page)
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Table 2. Basic demographic characteristics by the number of hospitalizations in the year after the 6-month visit for adult, first-time, kidney-only
recipients (United Network for Organ Sharing 2004–2007) (Continued)
Transplant characteristics Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Peak PRA 8.9 22.0 8.7 21.7 9.1 22.4 9.8 23.1 9.9 23.9 11.3 24.8 11.5 25.3 0.16
N % N % N % N % N % N % N %
PRA 0.36
0 107,12 68.4 8048 68.7 1651 67.7 554 66.0 260 67.9 104 62.7 95 60.1
1–20 3081 19.7 2268 19.4 493 20.2 169 20.1 73 19.1 36 21.7 42 26.6
21–80 1235 7.9 907 7.8 189 7.8 76 9.1 30 7.8 19 11.5 14 8.9
80þ 643 4.1 464 4.0 105 4.3 40 4.8 20 5.2 7 4.2 7 4.4
HLA match levela 53a 0.05
Zero 2759 17.6 2204 17.3 320 17.2 122 19.7 62 22.3 26 20.3 25 22.3
One 4267 27.1 3409 26.8 543 29.2 171 27.5 86 30.9 30 23.4 28 25.0
Two 2737 17.4 2200 17.3 336 18.1 110 17.7 45 16.2 27 21.1 19 17.0
Three 3211 20.4 2620 20.6 362 19.5 134 21.6 37 13.3 31 24.2 27 24.1
Four 1150 7.3 958 7.5 121 6.5 39 6.3 19 6.8 6 4.7 7 6.3
Five 844 5.4 704 5.5 90 4.8 25 4.0 15 5.4 5 3.9 5 4.5
Six 757 4.8 631 5.0 88 4.7 20 3.2 14 5.0 3 2.3 1 0.9
Complications N % N % N % N % N % N % N %
Delayed graft function <0.001
Yes 2534 14.3 1658 12.7 460 16.5 215 21.7 106 23.5 53 25.6 42 22.2
Acute rejection 370a <0.001
Yes 816 5.3 478 4.1 167 7.0 77 9.4 40 10.3 20 11.9 34 15.7
BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; HLA, human leukocyte antigen; PRA, panel-reactive antibody.
aIncludes missing values.
Figure 3. Mean estimated glomerular ﬁltration rate (eGFR) at 6
months after renal transplantation by the total number of hospitali-
zations in 1 year after this visit among adult, ﬁrst-time, kidney-only
transplant recipients, United Network for Organ Sharing 2004–2006.
Mean eGFR values are listed for each hospitalization number. The
red line indicates the trend line for mean eGFR values from 0 to 5 or
more late hospitalizations (P < 0.0001). The boxes represent the
interquartile range of eGFR, and the horizontal line represents the
median eGFR values.
FM Keong et al.: eGFR and Hospitalization CLINICAL RESEARCHeGFR and hospitalization in multivariable models for (i)
including patients who died (RR: 0.9872, 95% CI:
0.9844–0.9900), (ii) retransplant patients (RR: 0.9865,
95% CI: 0.9839–0.9891), and (iii) multi-organ trans-
plant recipients (RR: 0.9828, 95% CI: 0.9803–0.9854).
DISCUSSION
In this national, longitudinal study of more than 15,000
kidney transplant recipients across the United States, we
found that lower eGFR was associated with a higher
hospitalization rate among adult, ﬁrst-time kidney-only
transplant recipients, where a 10-unit decrease in the 6-
month eGFR was associated with an 11% increased risk
of hospitalization in the year after the 6-month trans-
plant follow-up visit. Additional risk factors for hospital
readmission included female sex, lower educational
attainment, diabetes, delayed graft function, previous
hospitalization, and length of stay at transplant. To our
knowledge, this is the ﬁrst study that identiﬁed risk
factors for hospital readmission at 6 months after trans-
plantation among a population of both publicly and
privately insured kidney transplant recipients. These
ﬁndings have signiﬁcant implications for the identiﬁca-
tion of patients at increased risk for late hospitaliza-
tion—a proxy for transplant-related poor health
outcomes—such as loss of graft function and mortality.
As expected, some of these risk factors, such as delayed
graft function, length of stay at transplant, and previous
hospitalization, may reﬂect complications early on that
lead to later hospitalizations. Our ﬁnding that patients
with fewer HLA mismatches have lower hospitalizationKidney International Reports (2016) 1, 269–278rates may have important clinical implications; further
studies are needed to determine whether policies and
practices to encourage greater HLA matching may
reduce health care resource utilization.
Our results are consistent with other studies that
identiﬁed a series of risk factors for early hospital
readmission. McAdams-Demarco et al.7 found that
among 32,961 Medicare primary kidney transplant275
Table 3. Multivariable zero-inﬂated Poisson modeling results for
association of eGFR with number of hospitalizations among adult,
ﬁrst-time, kidney-only transplant recipients (United Network for
Organ Sharing 2004–2007)
Adj. rate ratio
95% CI
P valueLower Upper
eGFR (per 10 ml/min per 1.73 m2) 0.89 0.89 0.89 <0.0001
Ethnicity
White (reference) 1 – – –
Black 1.03 0.97 1.11 0.33
Hispanic 0.93 0.85 1.01 0.09
Asian 0.93 0.81 1.07 0.31
Time 0.94 0.76 1.15 0.53
Sex
Male (reference) 1 – – –
Female 1.09 1.03 1.15 0.004
Recipient age (per 1 yr) 1.00 0.99 1.00 <0.0001
Education level
High school or less 1.13 0.99 1.29 0.06
Attended college or technical school 1.16 1.01 1.33 0.04
Associate/bachelor degree 1.10 0.95 1.27 0.20
Post-college graduate degree (reference) 1.00 – – –
Education level missing 1.22 1.06 1.41 <0.001
Insurance
Private insurance (reference) 1.00 – – –
Public insurance 1.12 1.05 1.19 0.004
Other 1.12 0.54 2.33 0.75
Length of stay (d) 1.00 1.00 1.01 <0.001
HLA match level
0 1.22 1.05 1.42 0.01
1 1.08 0.93 1.25 0.31
2 1.15 0.99 1.34 0.08
3 1.18 1.01 1.37 0.03
4 1.08 0.90 1.28 0.41
5 1.04 0.86 1.25 0.67
6 (reference) 1 – – –
Diabetes
No (reference) 1 – – –
Yes 1.18 1.25 1.11 <0.0001
Pretransplant dialysis
Yes (reference) 1 – – –
No 0.87 0.80 0.94 <0.001
Missing 0.45 0.34 0.61 <0.0001
Delayed graft function
No (reference) 1 – – –
Yes 1.19 1.27 1.11 <0.0001
Acute rejection episode
No (reference) 1 – – –
Yes 1.09 1.19 0.99 0.07
Donor hypertension
Yes (reference) 1 – – –
No 0.81 0.64 1.03 0.08
Missing 0.92 0.85 0.98 0.02
Previous hospitalizations (in ﬁrst 6 mo)
Yes (reference) 1 – – –
No 0.43 0.45 0.40 <0.0001
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate, HLA, human leuko-
cyte antigen.
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initial discharge from the transplant center. In both
this study and our study, risk factors for early hospital276readmission included older age, various patient
comorbidities, longer length of stay, and transplant
characteristics such as increased HLA mismatches.
However, unlike previous studies, we did not ﬁnd that
donor type impacted the risk of late hospitalization. We
also identiﬁed the 6-month eGFR as a novel marker for
late hospitalization. Information about both early and
late hospitalization may be useful in risk stratifying
patients at the time of either discharge after surgery or
at the 6-month posttransplant visit to monitor more
closely and potentially prevent poor adverse outcomes.
This study contributes to the growing body of
research investigating the association of eGFR and
transplant-related health outcomes, such as allograft
function13,14 and mortality.15–17 A meta-analysis of
105,872 participants from 14 studies found that eGFR
< 60 ml/min per 1.73 m2 is an independent predictor
of all-cause mortality in the general population.15
Furthermore, a retrospective study of 332 deceased
donor kidney transplant recipients found that patients
with kidneys from older donors or who experienced
delayed graft function and acute rejection episodes
were more likely to have deteriorating eGFR between
6 and 24 months after transplantation.16 A similar
retrospective study of 428 kidney transplant recipients
with a mean follow-up of 10 years found that changes
in eGFR over the ﬁrst year relates to poorer long-term
renal outcomes.17
Risk factors for decreased posttransplant renal
function include increasing donor age, receipt of a
deceased donor kidney, incidence of acute rejection,
and delayed graft function.18,19 As posttransplant renal
function is an independent risk factor for long-term
renal graft function, increased clinical scrutiny of pa-
tients with low eGFR may help reduce hospitalizations,
and both decrease the incidence of poor health out-
comes after transplantation and reduce cost. Closely
monitoring patients with low eGFR, speciﬁcally during
the ﬁrst year after transplantation, may prove espe-
cially beneﬁcial, as adverse events during that time
period have been shown to predict long-term graft
survival.20 Because most transplant recipients attend a
follow-up visit around 6 months posttransplant at their
transplant center, identifying patients with declining
eGFR at this time may allow risk stratiﬁcation of pa-
tients and the potential to intervene to prevent future
readmissions, graft failure, and mortality.
There were limitations to these analyses. Because
hospitalization data were only collected during a
limited time frame by UNOS (through 2007), we were
unable to examine more recent data or hospitaliza-
tions over a longer time period. Furthermore, we
could not assess early (30 days or less after surgery)
versus late hospital readmissions or the length of eachKidney International Reports (2016) 1, 269–278
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hospitalization date. We also did not have admission or
discharge diagnosis, and therefore cannot determine
whether patients were admitted to the hospital for
reasons unrelated to their kidney transplantation (e.g.,
elective procedures, pregnancy-related admissions,
etc.). There is also the possibility that hospitalizations
may be underreported to UNOS. There may be a
number of potential factors that also contribute to
hospitalization risk that were not captured in our
multivariable analyses, such as acute rejection, immu-
nosuppression medication, or other comorbidities that
were not measured or available in the UNOS Standard
Transplant Analysis and Research ﬁle data. Neverthe-
less, an increasing number of hospitalizations between
follow-up visits may still reﬂect poorer health status of
the patient as well as increased unplanned health costs.
Exclusion of patients who died or who had incomplete
follow-up may have resulted in selection bias; how-
ever, these patients had similar characteristics
compared with the study sample, and sensitivity ana-
lyses including these patients showed a similar effect
between eGFR and increasing hospitalization risk.
Differential access to medical treatment may result in
bias when hospital data are used as proxy measures21;
however, the vast majority of transplant patients in our
sample were insured. Finally, some covariates included
a high number of missing values; thus, for selected
covariates, we included missing values as a category.
Despite these limitations, this research had
numerous strengths. The use of a nationally represen-
tative surveillance database, containing information
regarding every organ donation and transplant event
in the United States, resulted in a large sample size with
a comprehensive set of covariates. This large sample
size allowed us to detect small differences in the rate of
hospitalization. In addition, risk prediction models for
hospitalization status based on eGFR can be used to
identify and treat patients at risk. Finally, because
these data are based on a nationally representative
surveillance system, they can be generalized to the US
population. Other research examining hospitalization
data using Medicare claims data may not be more
robust; however, they are limited to a Medicare-
insured population only and thus are not generaliz-
able to the US transplant population. This is the ﬁrst
study that we are aware of that has examined the as-
sociation between eGFR and posttransplantation hos-
pitalization among patients with both public and
private insurance, and thus results are more general-
izable to all transplant recipients.
Lower eGFR measured 6 months after transplantation
was signiﬁcantly associated with an increase in the
number of hospitalizations over time—even whenKidney International Reports (2016) 1, 269–278adjusting for a variety of covariates—in patients who
survived past 6 months. It is unclear whether there is a
clinically meaningful cut point for eGFR that would help
predict negative health outcomes, and whether there is
an optimal time frame after transplantation to screen for
changes in eGFR. As such, the ﬁndings warrant further
investigation into speciﬁc cut points for eGFR that can
be used as a clinical predictor of future hospitalization
among kidney transplant recipients. Prediction of such
preventable hospitalizations and early intervention to
prevent hospitalization based on serial eGFR measure-
ment may have signiﬁcant implications in cost reduction
and the prevention of morbidity and mortality associ-
ated with hospitalization after transplantation.
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